Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 443

1.

Priorities for screening and treatment of latent tuberculosis infection in the United States.

Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr.

Am J Respir Crit Care Med. 2011 Sep 1;184(5):590-601. doi: 10.1164/rccm.201101-0181OC.

2.

Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.

Auguste P, Tsertsvadze A, Pink J, Court R, Seedat F, Gurung T, Freeman K, Taylor-Phillips S, Walker C, Madan J, Kandala NB, Clarke A, Sutcliffe P.

Health Technol Assess. 2016 May;20(38):1-678. doi: 10.3310/hta20380. Review.

3.

Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.

Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, Rook G, Zumla A, Dheda K.

BMC Pulm Med. 2010 Feb 22;10:7. doi: 10.1186/1471-2466-10-7.

4.

Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.

Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR Jr, Marks SM, Linas BP.

JAMA Intern Med. 2017 Dec 1;177(12):1755-1764. doi: 10.1001/jamainternmed.2017.3941.

PMID:
29049814
5.

Systematic review of cost and cost-effectiveness of different TB-screening strategies.

Nienhaus A, Schablon A, Costa JT, Diel R.

BMC Health Serv Res. 2011 Sep 30;11:247. doi: 10.1186/1472-6963-11-247. Review.

6.

A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.

Campbell JR, Sasitharan T, Marra F.

Appl Health Econ Health Policy. 2015 Aug;13(4):325-40. doi: 10.1007/s40258-015-0183-4. Review.

PMID:
26129810
7.

Tuberculosis screening among HIV-infected patients: tuberculin skin test vs. interferon-gamma release assay.

Adams JW, Howe CJ, Andrews AC, Allen SL, Vinnard C.

AIDS Care. 2017 Dec;29(12):1504-1509. doi: 10.1080/09540121.2017.1325438. Epub 2017 May 9.

PMID:
28486818
8.

Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children.

Laskin BL, Goebel J, Starke JR, Schauer DP, Eckman MH.

Am J Kidney Dis. 2013 Jan;61(1):22-32. doi: 10.1053/j.ajkd.2012.06.004. Epub 2012 Jul 10.

9.

Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection.

Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, Yazdanpanah Y.

Int J Tuberc Lung Dis. 2010 Apr;14(4):471-81.

PMID:
20202306
10.
11.

Cost-effectiveness of Quantiferon®-TB Gold-in-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil.

Steffen RE, Caetano R, Pinto M, Chaves D, Ferrari R, Bastos M, de Abreu ST, Menzies D, Trajman A.

PLoS One. 2013 Apr 4;8(4):e59546. doi: 10.1371/journal.pone.0059546. Print 2013.

12.

Cost-effectiveness of alternative strategies for interferon-γ release assays and tuberculin skin test in tuberculous uveitis.

Ang M, Nguyen HV, Kiew SY, Chen S, Chee SP, Finkelstein E.

Br J Ophthalmol. 2015 Jul;99(7):984-9. doi: 10.1136/bjophthalmol-2014-306285. Epub 2015 Jan 8.

PMID:
25573149
13.

Cost-effectiveness of LTBI treatment for TB contacts in British Columbia.

Tan MC, Marra CA, Sadatsafavi M, Marra F, Morán-Mendoza O, Moadebi S, Elwood RK, FitzGerald JM.

Value Health. 2008 Sep-Oct;11(5):842-52. doi: 10.1111/j.1524-4733.2008.00334.x. Epub 2008 Jul 15.

14.

Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis.

Oxlade O, Schwartzman K, Menzies D.

Int J Tuberc Lung Dis. 2007 Jan;11(1):16-26.

PMID:
17217125
15.

Comparison of IGRA tests and TST in the diagnosis of latent tuberculosis infection and predicting tuberculosis in risk groups in Krakow, Poland.

Kruczak K, Duplaga M, Sanak M, Cmiel A, Mastalerz L, Sladek K, Nizankowska-Mogilnicka E.

Scand J Infect Dis. 2014 Sep;46(9):649-55. doi: 10.3109/00365548.2014.927955. Epub 2014 Jul 30.

PMID:
25073535
16.

Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries.

Kowada A, Takasaki J, Kobayashi N.

J Hosp Infect. 2015 Feb;89(2):99-108. doi: 10.1016/j.jhin.2014.10.002. Epub 2014 Oct 24.

PMID:
25559158
17.

Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions.

Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, Schwenke R, Burmester GR, Diel R, Feuchtenberger M, Kneitz C.

Ann Rheum Dis. 2012 Nov;71(11):1791-5. doi: 10.1136/annrheumdis-2011-200941. Epub 2012 May 14.

PMID:
22586160
18.

Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.

Haukaas FS, Arnesen TM, Winje BA, Aas E.

Eur J Health Econ. 2017 May;18(4):405-415. doi: 10.1007/s10198-016-0779-0. Epub 2016 Mar 12.

PMID:
26970772
19.

A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants.

Campbell JR, Krot J, Elwood K, Cook V, Marra F.

Mol Diagn Ther. 2015 Feb;19(1):9-24. doi: 10.1007/s40291-014-0125-0. Review.

PMID:
25579159
20.

Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands.

Erkens CG, Dinmohamed AG, Kamphorst M, Toumanian S, van Nispen-Dobrescu R, Alink M, Oudshoorn N, Mensen M, van den Hof S, Borgdorff M, Verver S.

Int J Tuberc Lung Dis. 2014 Apr;18(4):413-20. doi: 10.5588/ijtld.13.0589.

PMID:
24670695

Supplemental Content

Support Center